Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
Bénédicte DelcoigneLotta LjungSella A ProvanBente GlintborgMerete Lund HetlandKathrine Lederballe GrønRitva PeltomaaHeikki RelasCarl TuressonBjorn GudbjornssonBrigitte MichelsenJohan AsklingPublished in: Annals of the rheumatic diseases (2022)
The rate of ACS among patients with RA initiating bDMARDs remains elevated compared with the general population. As used in routine care, the short-term, intermediate-term and longer-term risks of ACS vary little across individual bDMARDs.
Keyphrases
- acute coronary syndrome
- rheumatoid arthritis
- preterm infants
- gestational age
- percutaneous coronary intervention
- antiplatelet therapy
- human health
- healthcare
- disease activity
- palliative care
- ankylosing spondylitis
- clinical practice
- risk assessment
- interstitial lung disease
- rheumatoid arthritis patients
- atrial fibrillation